错配修复蛋白MLH1、MSH2、MSH6及PMS2在结直肠癌中的免疫组化表达及临床意义  

Immunohistochemical Expression and Clinical Significance of Mismatch Repair Proteins MLH1,MSH2,MSH6 and PMS2 in Colorectal Cancer

作　　者：吴锦红 Wu Jinhong(Central South University Xiangya Second Hospital Guilin Hospital,Guilin,Guangxi 541001)

机构地区：[1]中南大学湘雅二医院桂林医院,广西桂林541001

出　　处：《中外健康》2024年第5期20-22,共3页

摘　　要：探究错配修复蛋白MLH1、MSH2、MSH6及PMS2在结直肠癌(CRC)中免疫组化表达及临床意义。选取2019年6月―2023年12月期间中南大学湘雅二医院桂林医院收治的236例结直肠癌患者的病理标本,经免疫组化法测定4种错配修复蛋白的表达情况,分析临床病理特征的关系。结果显示,236例CRC中4种错配修复蛋白表达缺失者为15例,微卫星不稳定性(MSI)为6.36%;临床病理特征表现中,MSI与发病部位、肿瘤直径、淋巴结转移、浸润深度呈显著相关(P<0.05);MLH1与PMS2的表达呈显著相关(P<0.05);MSH2与MSH6的表达呈显著相关(P<0.05)。研究发现,结直肠癌错配修复蛋白表达缺失后,与临床病理特征相关,通过检测错配修复蛋白MLH1、MSH2、MSH6及PMS2表达缺失情况,对结直肠癌患者诊断、治疗及预后评估有一定指导意义。To explore the immunohistochemical expression and clinical significance of mismatch repair proteins MLH1,MSH2,MSH6,and PMS2 in colorectal cancer(CRC).Pathological specimens of 236 colorectal cancer patients admitted to Central South University Xiangya Second Hospital Guilin Hospital from June 2019 to December 2023 were selected,and the expression of four mismatch repair proteins was determined by immunohistochemistry to analyze the relationship between clinical and pathological characteristics.The results showed that among 236 cases of CRC,15 cases had loss of expression of 4 mismatch repair proteins,and microsatellite instability(MSI)was 6.36%;In clinical pathological features,MSI is significantly correlated with the site of onset,tumor diameter,lymph node metastasis,and depth of infiltration(P<0.05);The expression of MLH1 was significantly correlated with PMS2(P<0.05);The expression of MSH2 and MSH6 showed a significant correlation(P<0.05).Research has found that the loss of mismatch repair protein expression in colorectal cancer is associated with clinical pathological characteristics.By detecting the loss of mismatch repair protein MLH1,MSH2,MSH6,and PMS2 expression,it has certain guiding significance for the diagnosis,treatment,and prognosis evaluation of colorectal cancer patients.

关 键 词：错配修复蛋白 结直肠癌 免疫形态 病理特征 

分 类 号：R735.37[医药卫生—肿瘤]